Advisory group reports on silent myocardial ischemia, coronary atherogenesis, and cardiac emergencies

Pepine, Carl J.; Cohn, Peter F.; Ellenbogen, Kenneth A.

doi:10.1016/0002-9149(94)90265-8

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with ischemic heart disease associated with episodes of silent myocardial ischemia (SMI) are known to have a poor prognosis similar to, or in some cases rather worse than, that associated with angina pectoris syndrome (1,3,4,8,10,16,25,27,30). Treatment for SMI should be implemented in the case of such patients, and nitrates are expected to be efficacious in this respect (2, 4-6, 8, 10, ll, 16, 22, 31).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Anti-anginal Drugs in the Treatment of Angina Pectoris Associated with Silent Myocardial Ischemia. Importance of Quantitative Holter ECG Data for Patient Activity.

Ino-Oka¹,

Sagawa

Takahashi

et al. 2000

Intern. Med.

View full text Add to dashboard Cite

MethodsWe evaluated the clinical efficacy of transdermal nitroglycerin (NTG-TTS), a patch application of a nitrate, in the treatment of 27 patients with angina pectoris who had asymptomatic myocardial ischemic (SMI) attacks, using a double-blind cross-over method. Evaluation was made using Holter ECGand patient activity data.Results In frequency and duration of continuation of SMIepisodes, no significant differences were noted between the observation and placebo treatment periods, while the values of both these parameters were decreased significantly in the active drug treatment period compared with those in the observation and placebo treatment periods. Critical heart rate, the heart rate at the initiation of ST-segment depression, was significantly higher during the period of active drug treatment than during the placebo treatment and observation periods. In SMIfrequency index, which was determined by adjusting the SMIfrequency for the numberof steps taken, there were no significant differences between the 3 periods. The SMI time index was significantly lower in the active drug treatment period than in the observation period. Conclusions These results indicated that the clinical evaluation of the efficacy of anti-anginal drugs against SMI should take into consideration individual patient activity data.

show abstract